CEO: @Feel_rx 10+ years Pfizer / Stryker 10+ years entrepreneur w/2 exits
Miami, FL
Joined December 2012
- Tweets6K
- Following1.9K
- Followers2.2K
- Likes14.8K
"Easier to get" is true. "Approved" is not. HHS is choosing not to enforce against licensed 503A pharmacies that meet 10 conditions, and USP just flagged that all six still lack quality standards. Easier access should come with more scrutiny, not less.
6 Peptides, Including BPC-157, Just Got Easier to Get. Here's What Health Experts Say Happens Next. menshealth.com/health/a74275…
3
50
The most honest line in a VC report this year: "the market's enthusiasm to date has outpaced the actual evidence." Agree. The peptide companies that last will close that gap with physician review and sourcing you can verify, not louder marketing. That's how we're building Feelrx.
@a16z State of Longevity report is out!
@evajsteinman and I surveyed 500 Americans to predict what's next.
We're also interviewing people at the cutting edge of health & tech about what they do themselves. My interview with @hubermanlab is out today.
55
I just saw “you can see everything last night” and it was a masterpiece. I personally met @ElizabethHolmes and Sunny Balwani and almost left Stryker to join them at #Theranos
I never thought that face to face interview with her would be so memorable but it felt genuine. She was extremely knowledgeable and offered me the position in person and I honestly wanted to join her.
I will be watching to see Theranos 2.0 come to life. I think the entire world will be watching.
#youcanseeeverything
2
1
98
Full post story line is here:
instagram.com/p/DfCacwKFiF8/…
19
Therapeutics for the healthy will be huge. Spent 10+ years at Pfizer and Stryker: the product is never just the molecule. It's who evaluates you, who makes it, and who follows up. That's the whole idea behind Feelrx.
If everyone else is slim, smart, energetic, sleeping really well and putting on muscle, you're not going to be the one person who isn’t.
Whether we like it or not (idk my view), therapeutics for the healthy will be one of the largest markets of all time.
GLP-1s were one of the first times a drug developed for a disease was used at scale for human enhancement.
The peptide boom is the clearest expression of this shift from healthcare to treat disease to healthcare to enhance life.
1
51
The gold rush framing is right, and that's the risk. When everyone rushes in, the shortcuts show up. The winners will be the ones with a physician deciding first and a pharmacy that can show where every ingredient came from. That's how we're building Feelrx.
The Peptide Gold Rush Has Begun
Prescription peptides have arrived, with blood tests, clinician oversight and a much bigger bill.
Superpower is taking preorders for BPC-157, TB-500 and MOTS-c at $149–$199 a month. Existing buyers are comparing vial prices. The clinic is selling everything around the vial.
The real question isn’t whether everyone will abandon the grey market. It’s whether the prescription package delivers enough measurable value to justify the premium
Full article below
1
48
The first real price tags for US-compounded peptides dropped yesterday. The internet immediately compared them to grey-market vials per milligram. That's the wrong math. 🧵
3
84
10+ years at Pfizer and Stryker taught me this: in healthcare, the product is rarely just the molecule. It's the system around it. Who evaluates you, who sources it, who follows up.
1
6
More legitimate players is good for patients. The bar is set now. At Feelrx we're building to it: physician review first, a licensed 503A pharmacy, ongoing check-ins. Join the waitlist for early access: feelrx.com/?utm_source=x&utm…
12
Got my seat at Health Innovation Labs!
Excited to be apart of @EudemoniaSummit with @fittinsider and a lot of new innovators in the health and wellness space!
Msg me if you will be going, let’s connect!
1
3
139
It's official. The HHS peptide compounding policy is in today's Federal Register.
What it does, what it doesn't, and how to weigh in. 🧵
2
54
How to weigh in: public comments are open for two weeks after publication, docket HHS-OASH-2026-0496 on regulations.gov. Patients, physicians, pharmacists: this is the window.
1
7
My take: this policy is the floor, not the ceiling. The programs worth trusting will go past it. That's what we're building at Feelrx.
Waitlist for early access: feelrx.com/?utm_source=x&utm…
9
What it isn't: FDA approval. HHS's own text says compounded drugs aren't FDA-reviewed for safety, effectiveness or quality.
It's also not a green light for "research use only" sellers. HHS says the goal is to move people away from them.
1
6
It can be pulled back. HHS may revisit it, in whole or in part, if a safety signal or product quality issue comes up.
Comments are open for two weeks after Friday's publication, on regulations.gov docket HHS-OASH-2026-0496.
1
11
My read: this rewards doing it right. A prescription, tested sourcing, a physician who decides. That's the model we're building at Feelrx.
Join the waitlist for early access:
feelrx.com/?utm_source=x&utm…
9
Appendix A is now public. Six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
Each is limited to specific forms and routes in Appendix B. Anything not on the list isn't covered.
1
45